Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Cancer, Clearly
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Cancer, Clearly
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Breast Cancer
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
Read More
CDK4/6 Inhibitors
Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Read More
CDK4/6 Inhibitors
A Pharmacist’s Perspective on CDK4/6 Inhibitors
Robert C. Wolf, PharmD
Read More
CDK4/6 Inhibitors
A Payer’s Perspective on CDK4/6 Inhibitors
Kenneth L. Schaecher, MD, FACP, CPC
Read More
CDK4/6 Inhibitors
A Nurse Navigator’s Perspective on CDK4/6 Inhibitors
Sharon S. Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN
Read More
Original Research
Impact of Pharmacist-Driven Educational Intervention on Documentation of Bowel Function Assessment in Patients with Cancer Who Are Using Opioids
Kimberly N. Flynn, PharmD, BCPS
,
Celestine Gochett, PhD, AOCNS
Read More
Original Research
Microbial Growth of Single-Dose Antineoplastic Drug Vials at 28 Days
Elizabeth R. Pritchard, PharmD, BCOP
,
J. Aubrey Waddell, PharmD, FAPhA, BCOP
,
Brad J. Crane, PharmD, BCPS
,
Amy M. Porter, PharmD
,
Susan Roberts, PharmD
,
Danielle M. Yates, PharmD
,
Angelia M. Thomas, MT (ASCP)
Read More
FDA Updates
The Value of Pre–FDA Approval Healthcare Economic Information Exchange Between Payers and Drug Manufacturers
Peter R. Fendt, PharmD, MBA
,
Brian Ung, PharmD, RPh
,
F. Randy Vogenberg, RPh, PhD
Read More
Case Reports
Aplastic Anemia in a Patient with Anaplastic Oligodendroglioma Postradiation and Concurrent Temozolomide Therapy: Case Report and Review of the Literature
Kirollos S. Hanna, PharmD, BCPS, BCOP
,
Robert Mancini, PharmD, BCOP, FHOPA
,
Matthew Burtelow, MD, PhD
,
Benjamin Bridges, MD
Read More
Symptom Management Overview
Prevention of Thromboembolism in Patients with Multiple Myeloma
Nicole Gerardo, PharmD
Read More
159
160
161
162
163
164
165
Page 162 of 199
Results 1611 - 1620 of 1986